<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40046">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728623</url>
  </required_header>
  <id_info>
    <org_study_id>E7080-J081-208</org_study_id>
    <nct_id>NCT01728623</nct_id>
  </id_info>
  <brief_title>A Study of E7080 in Subjects With Advanced Thyroid Cancer</brief_title>
  <official_title>A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally
      administered once daily (QD) in subjects with advanced thyroid cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants with Non-Serious Adverse Events and Serious Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in hematology, blood biochemistry, urinalysis, vital signs, ECG, physical test data</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From Study Start until progression of disease or date of death from any cause, whichever comes first, assessed up to 40 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From Study Start until date of death from any cause, assessed up to 40 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>E7080</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7080 capsule</intervention_name>
    <description>E7080 is administered as continuous once daily dosing in an uncontrolled manner</description>
    <arm_group_label>E7080</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Histologically or clinically diagnosed with thyroid cancer

          2. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-2

          3. Adequate laboratory values/organ function tests

        Exclusion criteria

        Subjects with following complication or disease history

          1. Brain metastasis

          2. Systemic severe infection

          3. Significant cardiovascular impairment

          4. QTc greater than 480 milliseconds

          5. Active hemoptysis

          6. Bleeding or thrombotic disorders

          7. Having greater than 1+ proteinuria on urine dipstick testing will undergo 24 hr urine
             collection for quantitative assessment of proteiuria

          8. Gastrointestinal malabsorption or any other condition in the opinion of the
             investigator that might affect the absorption of E7080

          9. Major surgery within 3 weeks before enrollment

         10. With co-existing effusion requiring drainage
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatsuya Sasaki</last_name>
    <role>Study Director</role>
    <affiliation>Oncology Clinical Development Section, Japan / Asia Clinical Research, Product Creation Unit, Eisai Product Creation System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Department of customer Joy, EJ</last_name>
    <email>_ML_CLNCL@hhc.eisai.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Koto-ward</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>September 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
